Scheduling delegate's final decisions: February 2012

Scheduling medicines and poisons

1 February 2012

Delegates' final decisions on scheduling matters initially referred to the October 2011 meeting of the ACCS#3, ACMS#4 or considered as delegate-only matters i.e. were not referred to an advisory committee.

How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Contents

  • Glossary
  • Part A - Final decisions on matters referred to an advisory committee
    1. Matters initially referred to ACCS#3 - October 2011
      • 1.1 Ametoctradin
      • 1.2 Deltamethrin
      • 1.3 Fluxapyroxad
      • 1.4 Indaziflam
      • 1.5 Prosulfuron
      • 1.6 Dicamba
    2. Matters initially referred to ACMS#4 - October 2011
      • 2.1 Azelastine
      • 2.2 Diclofenac
      • 2.3 Famciclovir
      • 2.4 Follistatin
      • 2.5 3, 4-Methylenedioxypyrovalerone (MDPV)
      • 2.6 Piper methysticum (Kava)
      • 2.7 Synthetic cannabinoids
  • Part B - Final decisions on matters not referred to an advisory committee
    1. Chemicals
      • 3.1 Penthiopyrad
    2. Medicines
      • 4.1 Entheogens
      • 4.2 Aflibercept
      • 4.3 Belatacept
      • 4.4 Ceftaroline fasamil
      • 4.5 Dapagliflozin
      • 4.6 Eribulin mesylate
      • 4.7 Ingenol mebutate
      • 4.8 Lixisenatide
      • 4.9 Pitavastatin
      • 4.10 Recombinant Neisseria meningitidis
      • 4.11 Rifaximin
      • 4.12 Taliblucerase alfa
      • 4.13 Velaglucerase alfa
      • 4.14 Vemurafenib
    3. Editorials and errata
      • 5.1 "Oromucosal" definition
      • 5.2 Dimethyl sulfoxide
      • 5.3 Emodepside
      • 5.4 Sodium lauryl sulfate
      • 5.5 Laureth carboxylic acids

Top of page